With a combined revenue of $21 trillion and $2.1 trillion in profits, the 2026 Fortune 500 is the definitive list of America's largest companies.

Fortune 500

The 300 companies on this year’s list brought in over $12.5 trillion in revenue for the latest 12 months, with the median revenue figure at $24 billion.

America's Most Innovative Companies

AI is a major force shaping this year’s list—but it’s far from the only story.

World's Most Admired Companies

Almost $20 trillion in revenue—and a record-breaking $1.87 trillion in profits. Introducing the 2025 Fortune 500, the definitive list of the biggest companies in America.

The 300 companies on this year’s list brought in over $12.6 trillion in revenue for the latest 12 months, with the median revenue figure at $22 billion.

Leaders in all industries rely more than ever on Big Tech—and appreciate the giants that deliver, at scale, without drama.

Industries included in the sector are insurance and managed care, medical products and facilities, pharmacy services, and pharmaceutical companies.

Fortune Sector Leaders: Health Care

The Fortune 500, in its 70th year in 2024, ranks the biggest U.S. companies by revenue.

The 26th edition of the list shows how much esteem Big Tech giants command among other business leaders.

The 25th Fortune World’s Most Admired Companies list suggests that tech giants’ peers respect them as much as ever.

The 300 companies on this list are transforming industries from the inside out.

The Fortune 500, in its 69th year in 2023, ranks the biggest U.S. companies by revenue.

Just as it dominates our economy, Big Tech now dominates Fortune’s annual ranking of corporate reputation.

This year’s Fortune 500 marks the 68th running of the list.

After a year in which humanity leaned more heavily than ever on tech giants, see which companies topped Fortune's ranking of corporate reputation.

This year’s Fortune 500 marks the 67th running of the list.

F500-2021-324-Quest Diagnostics

Millions of people turn to the laboratory company to conduct the important tests that track cholesterol levels, white blood cell count, and other crucial measurements that ensure healthy lives. Quest Diagnostics also helps pharmaceutical companies conduct the clinical trials that could lead to life-saving treatments.

For an astounding 13th straight year, Apple claims the top spot in Fortune’s annual ranking of corporate reputation, based on a survey of almost 3,800 executives, directors, and analysts.

This year's Fortune 500 marks the 66th running of the list.

Quest Diagnostics Flies Coronavirus Tests and Samples Across the United States

The clinical diagnostics company’s services range from routine blood work to gene-based testing.

Here are the World's Most Admired Companies for 2019 as ranked in their industries. See who made the list.

This year's Fortune 500 marks the 65th running of the list.

Here are the World's Most Admired Companies for 2018 as ranked in their industries. See who made the list.

This year's Fortune 500 marks the 64th running of the list.

Here are the World's Most Admired Companies for 2017 as ranked in their industries. See who made the list.

This year's Fortune 500 marks the 63rd running of the list.

Here are the World's Most Admired Companies for 2016 as ranked in their industries. See who made the list.

This year's Fortune 500 marks the 62nd running of the list.

Business insiders have spoken: Asked which companies they most admire, more than 4,100 executives, directors, and analysts chose these top 50 All-Stars.

This year's Fortune 500 marks the 61st running of the list. Wal-Mart claims the top spot again. See who made the list.

Wal-Mart stayed on top as its sales crept closer to half-a-trillion dollars. Apple moved into the top five. And UnitedHealth Group continued its steady climb. 

Sector

Industry

Current All-Star Rank

Previous All-Star Rank

Industry Rank

Previous Industry Rank

Overall Score

Innovation

People Management

Use of Corporate Assets

Social Responsibility

Quality of Management

Financial Soundness

Long-Term Investment Value

Quality of Products/Services

Global Competitiveness

Strongest Dimension

Years on list

Previous rank

State

Key Financials (last Fiscal Year)

Revenues ($M)

Profits ($M)

Assets ($M)

Total Stockholder Equity ($M)

Profit Ratios

Profit as % of Revenues

Profits as % of Assets

Profits as % of Stockholder Equity

Earnings Per Share (last Fiscal Year)

Earnings Per Share ($)

EPS % Change (from prior fiscal year)

EPS % Change (5 year annual rate)

EPS % Change (10 year annual rate)

Total Return

Total Return to Investors (last year)

Total Return to Investors (5 year, annualized)

Total Return to Investors (10 year, annualized)

Quest Diagnostics is a major diagnostic testing company, offering lab and direct-to-consumer tests that touch one in three U.S. adults every year and half the nation’s hospitals and doctors. Since its 1967 founding, the company has grown to have a presence in 130 countries. It works with hospitals, doctors, patients, insurers, government agencies, employers, and pharmaceutical companies, with more than 2,250 locations in the U.S. Quest operates under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands.

Q2 2026

Q1 2026

Q4 2025

Q3 2025

Q2 2025

Q1 2025

Q4 2024

Quest Diagnostics (DGX): Company Profile, Stock Price, News, Rankings

legacy

Quest Diagnostics

quest diagnostics

Welcome to the Quest Diagnostics First Quarter twenty twenty five Conference Call. At the request of the company, this call is being recorded. The entire contents of the call, including the presentation and question and answer session that will follow, are the copyrighted property of Quest Diagnostics with all rights reserved. Any redistribution, retransmission or rebroadcast of this call in any form without written consent of Quest Diagnostics is strictly prohibited. Now I'd like to introduce Sean Bevec, Vice President and Investor Relations for Quest Diagnostics.

Thank you, and good morning. I'm joined by Jim Davis, our Chairman, Chief Executive Officer and President and Sam Samad, our Chief Financial Officer. During this call, we may make forward looking statements and will discuss non GAAP measures. We provide a reconciliation of non GAAP measures to comparable GAAP measures in the tables to our earnings press release. Any actual results may differ materially from those projected.

Risks and uncertainties that may affect Quest Diagnostics' future results include, but are not limited to, those described in our most recent annual report on Form 10 ks and subsequently filed quarterly reports on Form 10 Q and current reports on Form eight ks. For this call, references to reported EPS refer to reported diluted EPS and references to adjusted EPS refer to adjusted diluted EPS. Growth rates associated with our long term outlook projections including consolidated revenue growth, revenue growth from acquisitions, organic revenue growth and adjusted earnings growth are compound annual growth rates. Now here is Jim Davis.

Thanks Sean and good morning. In the first quarter we delivered strong revenue growth of approximately 12% including nearly 2.5% in organic growth as demand rebounded in March following weather impacts early in the quarter. Our growth was due to contributions from acquisitions and large enterprise accounts, demand for our advanced diagnostics portfolio and expanded health plan access. We also continue to expand our use of automation, robotics and AI with the goal of improving quality, customer and employee experiences and productivity. We are reaffirming our revenue and adjusted EPS guidance for the full year 2025.

Now before turning to highlights from the quarter, I'd like to briefly comment on the recent court case that vacated the FDA rule to regulate laboratory developed tests as medical devices. The court's decision will ensure patients and providers can continue to access innovative laboratory testing services regulated under CLIA without additional regulatory costs to comply with the FDA LDT rule. We also recognize that several growing areas of our business already operate under the FDA's existing quality management system regulations, including companion diagnostics and lab services for clinical trials. In addition, our business is increasingly global as we expand in Canada through LifeLabs and provide reference testing for many countries. We continue to invest in quality management processes and technologies to navigate the complexity of the global regulatory environment.

Now I'll recap our strategy and discuss highlights from the first quarter. Then Sam will provide more detail in our results. Our strategy to drive growth is focused on delivering solutions that meet the evolving needs of our core clinical customers, physicians and hospitals, as well as customers in the higher growth areas of consumer initiated testing, life sciences and data analytics. We enable growth across our customer channels through faster growing advanced diagnostics in five key clinical areas, which are advanced cardiometabolic, autoimmune, brain health, oncology and women's and reproductive health. In addition, acquisitions are a key growth driver and our strategy emphasizes accretive outreach purchases and independent labs.

Finally, we are focused on driving operational improvements across the business with the deployment of automation, robotics and AI for improved quality, customer and employee experiences and productivity. Here are some of the updates on the progress we have made in these areas in the first quarter of twenty twenty five. In the physician channel, we delivered revenue growth in the high teens driven largely by acquisitions. Organic revenue growth in the physician channel was mid single digits. Our expanding portfolio of advanced diagnostics continued to deliver solid growth.

We also generated volume and revenue growth through access to new geographies as a result of new health plan partnerships that took effect on January 1. In addition, we also grew from large enterprise accounts, including functional medicine providers, which are often early adopters of advanced diagnostics tests that over time move to broader adoption. For example, we saw impressive uptake of our novel PFAS forever chemicals test, which we launched a little over one year ago. Our ability to scale diagnostic innovation is attractive to large enterprise organizations seeking to improve access, quality, and affordability. During the quarter, Quest was named as the first independent national lab to be selected to the OptumHealth Preferred Lab Network.

The OptumHealth PLN requires labs to meet rigorous quality and economic criteria to improve patient affordability and access. The OptumHealth network represents more than 85,000 Optum employed, contracted and affiliated physicians. Our addition to this PLN is an example of our attractiveness as a partner to enterprise providers seeking to improve quality and economic value. We also announced an agreement to provide comprehensive lab testing for Fresenius Medical Care's dialysis center serving more than 200,000 kidney dialysis patients in The U. S.

Under a separate agreement, we also plan to acquire select lab assets from Fresenius Medical Care in The U. S. In the hospital channel, revenue growth in the quarter was largely driven by contributions from our collaborative lab solutions, formerly known as professional lab services. Running a lab and developing lab tests requires investing in equipment, hiring specialized talent and keeping pace with innovation in lab technology. Health systems continue to face supplies inflation, workforce challenges, and reduced access to capital.

Through our reference testing, co lab solutions, and outreach lab acquisitions, Quest provides hospitals with strategic options for accessing best in class diagnostic innovation without having to maintain a lab. At our recent Investor Day, we shared our plans to expand in three high growth areas, consumer initiated testing, life sciences, and data analytics. We recently enhanced the online shopping experience of our consumer initiated test platform, questhealth.com, streamlining the order process, which contributed to a sharp uptick in first time orders during the quarter. We also introduced 10 new tests on the platform. Questhealth.com features fast access, physician consults, and for STIs and several other conditions, access to prescriptions for treatment.

We recently shared our long term outlook for double digit growth in advanced diagnostics across five key clinical areas. Advanced cardiometabolic and autoimmune testing both grew at double digit rates similar to trends seen last year. These areas help providers support preventative care for patients by identifying early health risks conventional lab tests can miss. In brain health, we generated double digit growth from our innovative AD DETECT blood tests for Alzheimer's disease. We are particularly excited about our latest AD DETECT blood test panel, which we launched this month.

This new panel combines results of amyloid beta and p tau two seventeen, two well established Alzheimer's biomarkers to give physicians even greater confidence to confirm Alzheimer's brain pathology in symptomatic patients. In women's and reproductive health, prenatal and hereditary genetic testing grew double digits. In March, we launched a solution that enables a patient to self collect a specimen for HPV cervical cancer screening at a doctor's office. We plan to roll out this self collect option at our 2,000 patient service centers in The US early next month, complementing our STI related self collect option, which has already seen high rates of adoption since its launch last year. During the quarter, we started to receive commercial orders for our Haystack MRD test for assessing early risk of cancer recurrence.

We are investing in our connectivity with electronic medical records preferred by oncologists to improve ease of account setup and ordering. For instance, we plan to deploy Haystack MRD via Epic's Aura specialty EMR module later this year. Finally, Quest continues to be at the forefront of serving public health needs. We saw an uptick in our measles offerings, including testing that can be used for diagnosis or to assess vaccination status or prior infection. Turning to operational excellence.

We continue to target 3% annual cost savings and productivity improvements through Invigorate. We are automating several areas of our laboratories from tuberculosis testing to cervical cancer screening to improve quality, customer and employee experiences and productivity. We also recently shared goals for Project Nova, which we expect will modernize and simplify our entire order to cash process. While this initiative will take several years to fully implement, we expect to realize the benefits sooner, including lower IT spend and improved productivity. Project Nova will also support our ability to optimize data insights and GenAI.

During the quarter, we announced a collaboration with Google Cloud to streamline data management and employ GenAI to personalize customer and employee experiences. Finally, I want to thank our more than 55,000 Quest and LifeLabs colleagues for their dedication to living the Quest purpose, working together to create a healthier world, one life at a time. And now Sam will provide more details on our performance and 2025 guidance. Sam?

Thanks, Jim. In the first quarter, consolidated revenues were $2,650,000,000 up 12.1% versus the prior year. Consolidated organic revenues grew by 2.4%. Revenues for Diagnostic Information Services were up 12.7 compared to the prior year, reflecting recent acquisitions as well as growth in our key physician and hospital channels. Total volume measured by the number of requisitions increased 12.4% versus the first quarter of twenty twenty four with organic volume down by 0.9.

During the quarter, weather in one less day versus the prior year reduced volume growth by approximately 160 basis points. Total revenue per requisition was up 0.3% versus the prior year, driven primarily by an increase in the number of tests per rec, mostly offset by the impact of the LifeLabs acquisition, which carries a lower revenue per requisition. On an organic basis, revenue per rec was up 3.6% in the quarter versus last year. Unit price reimbursement was relatively flat consistent with our expectations. Reported operating income in the first quarter was $346,000,000 or 13% of revenues compared to $300,000,000 or 12.7% of revenues last year.

On an adjusted basis, operating income was $4.00 $6,000,000 or 15.3% of revenues compared to $349,000,000 or 14.8% of revenues last year. The increase in adjusted operating income was due to the impact of recent acquisitions and organic revenue growth, partially offset by the impact of weather, one less day versus the prior year and wage increases. Reported EPS was $1.94 in the quarter compared to $1.72 a year ago. Adjusted EPS was $2.21 versus $2.04 the prior year. EPS in the first quarter was impacted by higher interest expense versus the prior year.

Cash from operations was $314,000,000 in the first quarter versus $154,000,000 in the prior year. Turning now to full year 2025 guidance. Despite the economic uncertainty and unstable macro backdrop and given Quest's essential role in healthcare and comparative resilience, we are reaffirming guidance for revenues and adjusted EPS. Therefore, revenues are expected to be between $10,700,000,000 and $10,850,000,000 Reported EPS now expected to be in a range of $8.62 to $8.87 and adjusted EPS to remain in a range of $9.55 to $9.8 Cash from operations is now expected to be approximately $1,500,000,000 and capital expenditures are expected to be approximately $500,000,000 Our twenty twenty five guidance reflects the following considerations. Our revenue guidance continues to assume approximately 3% organic revenue growth with the remainder coming from the acquisitions completed in 2024 and announced to date.

It does not assume any contribution from prospective M and A. We continue to anticipate that Haystack Oncology will be slightly less dilutive versus the prior year. We are making investments in 2025 related to Project Nova, which we expect will modernize our entire order to cash process. Also, despite the decision by a federal court to vacate the FDA rule on lab developed tests, we still intend to make some investments this year to strengthen our regulatory capabilities to serve our growing global and life sciences businesses. Operating margin is expected to expand versus the prior year.

We continue to anticipate net interest expense to be approximately $275,000,000 Adjusted tax rate is expected to be approximately 25%. Our share count for the full year is expected to be approximately 114,000,000 diluted shares outstanding. Finally, we raised our operating cash flow guidance by $50,000,000 which primarily reflects a pretax gain to be taken in Q2 related to a payroll tax credit under the CARES Act that we received in April. With that, I will now turn it back to Jim.

Thanks Sam. To summarize, we delivered strong consolidated and organic revenue growth in the first quarter as demand rebounded in March following weather impacts early in the quarter. In addition to acquisitions, key drivers of growth included large enterprise partnerships, advanced diagnostics and expanded health plan access. And we are reaffirming our revenue and adjusted EPS guidance for the full year 2025. Now we'd be happy to take questions.

Thank you. We will now open it up to questions. At the request of the company, we ask that you please limit yourself to one question. If you have additional questions, we ask that you fall back into the queue. To be placed into the queue, please press star one from your phone.

Our first question comes from Luke Sergott with Barclays. Your line is open. You may ask your question.

Great. Thanks guys. Good morning. I just wanted to touch on the organic, the volumes that you guys had. When you kind of break it down on a test per day, it's roughly flattish to what you guys had last year.

And so as you're thinking about as you roll out through the rest of the year, the pacing going to be relatively similar to what we had last year? Anything to call out there from days or what you guys have baked in from the downside from weather, etcetera?

Yes. So good morning, and thanks for your question. So just on the organic volume, reported was down 90 basis points. But if we correct for the leap year impact and the weather impact year over year, it would have increased that by a 60 basis points. So we would have been up, you know, about, close to 1%.

Now that really does compare, you know, with what we saw both in, the third quarter and fourth quarter last year. There was a progression through 2024, but only because the first and second quarter were really, still impacted by COVID from 2023. The other thing I'd mentioned is, you know, while January and February were certainly soft because of the weather, we did see a nice bounce back, in particular during the last three weeks of March. And I would tell you, our volume trends in the first '19, '20 days of April have also been consistent, with our expectations and what we saw last year. So, I think we're pleased with the utilization levels that we're seeing out there right now.

Thank you. Our next question comes from Kevin Caliendo with UBS. Your line is open. You may ask your question.

Thank you. Good morning. Thanks for taking my question. Wanna ask the tariff question and just try to understand sort of what kind of exposures Quest has to this, you know, in in the context of how much of your supply costs come OUS, how much of it is fixed contracts, how should we think about the risks of this going forward? Have you adjusted your your model or your expectations for tariffs in any way?

Any details you can provide would be super helpful.

Sure. Thanks, Kevin. Let let me just start with look. We buy about $2,000,000,000 of, you know, reagents supplies, and that 2,000,000,000 is capital, you know, equipment cost and also, you know, service contracts. So about $2,000,000,000 of of total spend.

Now, first of all, less than 1% of that, we source directly from China, ourselves. Okay? And, we have plans already activated where that less than 1% small number, we are moving some of those. And and by the way, that that less than 1% is is pre analytical supplies, gowns, gloves, masks, tubes, you know, really simple types of things. So some of it we've already moved.

We're in the process of moving others. So we actually think our exposure there is is not that great. Now if you if you come back to that 2,000,000,000, about 75 to 80% of that of of that spend is really reagents and supplies for the laboratory. And and and and that is actually manufactured here in The US. So we can have global suppliers like Siemens and Roche, but the manufacturing of that is in The US.

So, again, we believe our exposure is small. The other thing I'd say is most of our supplies are under multiyear contracts. Obviously, those contracts come up every four to five years. So 20% will come up this year. But we compete those things.

So as we said in the prepared remarks, any tariff impact we think we can cover at this point given the guidance that we've put out there.

Yes. And I would just add, Kevin, this is obviously based on under current law and current regulations. So this is what we're assuming based on today, what we know today. It's the impact is not zero, but the impact is very manageable for us, and it's baked into our current guidance.

That's super helpful. I appreciate the color. Can I ask a quick follow-up? Just in the last week or so, we've read some stories about strikes up in LifeLabs. The stories don't give a ton of details.

It sounds like it's somewhat organized but nonunion. Can you just maybe talk about what that is and if it's impacting LifeLabs in any way or impacting the potential accretion from LifeLabs?

I'm sure, Kevin. So, first of all, the strike is just on the British Columbia side. Recall, LifeLabs broadly participates in the Ontario marketplace and the British Columbia marketplace. British Columbia is actually the smaller of the two sides. There are about 1,200 employees that are involved in the strike.

Those 1,200 employees are part of a much bigger union of roughly 70,000 employees called the BCGEU. It's largely a public service union. Now there's certain statues about how strikes are conducted in British Columbia, and one of those is you can only we have a 28 patient service centers in British Columbia. You can actually only strikes at 17 of those 128. So on any given day, actually, there's there's a small amount of people that are actually out on strike, and our management team in British Columbia has to backfill those open positions, which they've been doing.

We do have a mediator involved. We are making progress, and we hope to have things settled within the next thirty to forty five days.

Thank you. Our next question comes from Patrick Donnelly with Citi. Your line is open. You may ask your question.

Hey, guys. Thank you for taking the questions. Sam, maybe just a quick one. Just on pacing on margins. Can you talk a little bit about 2Q?

I know typically seasonally that's the strongest quarter. So I just want to talk through margins and earnings there. Any impact again from some of the tariff noise, freight surcharges, things like that? And then just quickly LifeLabs outside the strike, just how it performed this year

Sure. And good morning, Patrick. Listen, let's talk first about margins in Q1 and then I'll talk about the pacing and address your question about LifeLabs. Q1 margins came in operating margins at 15.3%. So a 50 basis point expansion from prior year that was driven by volume impacted somewhat negatively by the weather impacts that we talked about, which were more severe than what we saw last year.

But in general, strong margins 15.3% operating margins. As we think about the full year, Patrick, the pacing is really very consistent with what we expect to see in terms of traditional or historic seasonality, even going back pre COVID seasonality because COVID impacted a little bit the seasonality. So traditionally, what we've seen and I'm talking really here EPS pacing, not necessarily operating margin pacing. But EPS pacing, usually what we see is roughly 49% in the first half of the year, about 51% in the second half of the year. And so you see Q2 being the best quarter, Q3 slightly lower than that, Q4 lower than Q3.

And then usually Q1 is actually the lowest quarter of the year in terms of EPS contribution. So that's what we expect in terms of pacing. In terms of expectation for full year 2025, still the expectation is that we continue that we grow operating margins rate versus last year, both dollars and rate. In terms of LifeLabs

Yeah. Let me just give you a little color on LifeLabs in the quarter. First of all, I think, as you all know, most of the revenue is capitated. So there's generally not surprises on the revenue side. There's a small amount of patient, it's physician patient physician revenue where you're selling tests directly to physicians outside of the capitated agreement.

But the revenue was really basically in line with our expectations. On the margin side, as we indicated, we expect to have LifeLabs at the corporate average within two to three years. And I would just tell you, we made, again, nice progress in the quarter. We've seen quarter over quarter improvements in margin rate, and, we expect, to be, if anything, on the early side of our plans of having it at the company corporate margin in two to three years.

Thank you. Our next question comes from Elizabeth Anderson with Evercore ISI. Your line is open. You may ask your question.

Hi, guys. Good morning. Thanks so much for the question. Are tariffs or any of the, potential hospital reimbursement challenges, creating an opportunity in the hospital lab management space or outreach space, or you would just say sort of too soon? If you could just sort of talk about the maybe the progression of some of those quest questions and debates that you've been hearing recently.

Yeah. I think it's a bit too soon. It it's not to say we won't contemplate price increases if tariffs start to hit us in a meaningful way. As you know, you know, the health plan contracts, you know, probably don't give us a chance to go back and and open those up. Having said that, you know, 25 20 to 25% of the contracts come up every year.

And if we're seeing a meaningful impact on our business, we're certainly gonna try to pass that through. The health, you know, health system pricing landscape, I I would still say, is the most challenging of all that we deal with. But, again, if we are hit in a meaningful way, we're certainly gonna try to pass that along to both health systems, client bill, consumer bill, and anything outside of of health plans.

Sorry, Jim. I meant more like our hospitals, like, increasingly seeking relation like, in your acquisition strategy. Sorry if my question wasn't clear.

Okay. You know, the the funnel of opportunities on what we now call the our co lab, collaborative lab services agreement, continues to be very robust. We're in the process of negotiating with several, institutions on this. So, if anything, you're right. It can accelerate those opportunities if, if suppliers start to pass those tariffs, in the form of price increases to our to our health systems.

Thank you. Our next question comes from Michael Cherny with Leerink Partners. Your line is open. You may ask your question.

Good morning, and thanks for taking the question. Maybe to kind of get at the market dynamics in a little different fashion. You know, I I appreciate the color you gave on the tariff impact. That's certainly helpful. I would assume that other entities in the market, smaller than you and your largest peer, are gonna be in a slightly more challenging position in trying to get to managing any offsets on costs similar to potentially what happened with the inflationary environment on the wage side from a couple of years back.

How do you think about the strategic discussions you're having with payers on potentially driving more share about opportunities you have to service, a wider swath of their membership bases given your reach, your scale, and your ability to absorb, and or offset any of these cost dynamics? Curious I know it's early, but if you're seeing any changes in terms of strategic payer dynamic and then looking to you, more closely given you're on much more stable financial footing.

Yeah. So, Mike, I I would tell you that, our discussions and collaborations, with the health plans, are ongoing continuous. As you know, we have all sorts of programs in place on the redirection of work to try to redirect work from expensive out of network labs, from expensive health system labs. Several of our large payers, we have, you know, collaborative relationships. Relationships that provide us with information of physicians that are using these very expensive labs, and our teams go and work those lists really hard and try to convert that over.

As we also mentioned in the prepared remarks, we are now a preferred lab network provider for OptumHealth Services, and that went into place during the quarter. And in a similar way, we work with the roughly 85,000 physicians that are in the Optum network. We work with the management team at OptumHealth to try to redirect as much of that work into, you know, labs to Quest Diagnostics, where you're gonna get really great quality at at, at a great value. So if anything, yeah, I agree. These tariffs, may, push probe and and and help do the and move that work even quicker.

you. Our next question comes from Pito Chickering with Deutsche Bank. Your line is open. You may ask your question.

Hey, good morning guys. A follow-up to Kevin's question on the tariffs and I think I missed one of the numbers that you gave out. Of the $2,000,000,000 spend, what's the spend on supplies on the sort of low end, that could be sourced, in China like syringes, gloves and gowns?

Well, what we did what I I didn't give that exact number. The number I gave is of the 2,000,000,000, less than 1% is sourced directly from suppliers in China by Quest Diagnostics. So, and within that, less than 1% are mostly preanalytical supplies, so gowns, gloves. Now that's not to say that, the entirety of our preanalytical low tech supplies comes out of China. They come across, you know, in all, in all parts of the world.

Now what I said is to minimize our exposure on that spend in China, we've we've actively been moving from suppliers, in China to outside of China, including suppliers in The U. S, including suppliers around the rest of the globe where tariffs are significantly lower.

Yeah. But a couple of percentages though, Pito, just to keep in mind is we also said roughly 80% is basically manufactured or sourced in The U. S. So at least based on the law today, impacted by tariffs. And also 70% to 80% of the total supplies that we have are under contract.

So they have fixed pricing, and we think we can manage the exposure. The exposure is not zero, but we think it's manageable.

Yeah. Just to clarify, the 80% that is manufactured in The US are really the reagents Right. The expensive reagents for running the lab test. Yep.

Right. So so the 2 billions or 20% of the price source outside The US, a combination of, believe, split between, you know, Malaysia, China or, you know, a series other sources. I I just heard of should think about that. Right?

Okay. Okay. Fair enough. And then, for your M and A pipeline, just can you sort of talk about sort how the pipeline looks? It's just been a while since we haven't seen a deal closed in a quarter.

Are you going back in the cash flow savings since fourth quarter twenty twenty three? Does the pipeline for our reach still look as robust as it has been? Do you sort of see the pace continuing as expected? Or as hospitals continue to do well operationally, excluding the current political environment, do you see that change the pace of as you view outreach deals?

The funnel is still healthy, and it's a mix of hospital outreach types of endeavors plus small regional labs that are still left out there. So I think it's health healthy. We did, as we mentioned in the prepared remarks, enter into a collaboration with Fresenius Medical Services, where we are now going to start doing the lab testing associated with dialysis treatment in our regional labs. In addition, Fresenius also provided third party laboratory testing services for other dialysis centers, and we purchased that small book of business, and that too will come into Quest Diagnostics. So that represents, as I mentioned, over two hundred thousand dialysis patients, patients getting tested at least once a month, and, that represents a nice chunk of volume that will be coming our way when we officially close on this later in this year.

you. Our next question comes from Tycho Peterson with Jefferies. Your line is open. You may ask your question.

Hey, this is Noah on for Tycho. Thanks for taking our question. I wanted to ask about Haystack, particularly, you're receiving commercial orders, how you're thinking about reimbursement submissions and timelines. And then on the data side, anything you think still needs to be done to generate more evidence? Yes.

So as we discussed in the remarks, we launched the Haystack assay commercially in the quarter. We are pleased with the progress that we've made. We had over 75 customers that were part of the early experience program, and many of those customers are continuing to do business with Quest Diagnostics. In terms of reimbursement, the test is being offered to Medicare and, patients in commercial plans, and we offer to any patient. We've just started to submit for reimbursement.

We're working with, one of the big MACs on, getting the coding and coverage policies in place. And, you know, that requires a bit of time, and it requires a bit of reimbursement experience, and that experience is is well underway.

You know? And in terms of evidence, stay tuned. We'll we'll continue to work on potential evidence as we as we move forward here.

Yeah. You'll you'll see more and more publications in, the fruits of the, ongoing clinical trials that Haystack had in place even before we purchased them, well well more than a year ago.

Thank you. Our next question comes from David Westenberg with Piper Sandler. Your line is open. You may ask your question.

Hi. Thank you very much. So I just wanted to, on the collaboration with Google Cloud to streamline data management and, use generate GeniAI to personalize customer experience and employee experience exploring experiences. How does that translate into some of the financial benefits? I was thinking about maybe the personalized customer retain personalized customer one.

Maybe you you know, you get higher compliance rate in testing or something like that. You know, does the employee one lead to maybe, some some benefits from from the cost side? What kind of specific KPIs should we be looking at, to measure success in here? This big

Sure. So step one in the overall relationship with Google Cloud is is simply the movement of what I call pockets of that result that reside in, a lot of various places across Quest Diagnostics, mostly on premise. So, the benefits of moving that information to the cloud, I'll I'll give you a couple. One, we have a data analytics business. And, whenever we have to search the entire Quest database, you know, it's a complex task today to, you know, basically conduct searches across data that's sitting in pockets all across the country in various places.

Quest Diagnostics (DGX) Q1 2025 Earnings Call Transcript

Company Participants